Pharmaceutical compositions containing ginsenoside, safflor yellow and its preparation and application

A technology of safflower yellow pigment and total ginsenosides, which is applied in drug combinations, medical preparations containing active ingredients, drug delivery, etc., can solve the problems of human bleeding and difficulty in clinical application by doctors, and achieve the effect of preventing bleeding

Inactive Publication Date: 2005-04-06
张正生
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Cardiovascular and cerebrovascular diseases have also become one of the common frequently-occurring diseases of the elderly, especially cerebrovascular diseases. It is widely used clinically in the treatment of cardiovascular and cerebrovascular diseases, and has made an important contribution to relieving the pain of patients; but in the long-term clinical application process, it is also

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Pharmacological Experiments on Bleeding Time and Bleeding Volume in Mice

[0050] Experimental drugs: each group of preparations of the present invention (provided by Beijing Ganluchun Science and Technology Co., Ltd.) commercially available safflower injection (Sichuan Ya'an Sanjiu Pharmaceutical Co., Ltd.) normal saline (provided by Beijing Ganluchun Science and Technology Co., Ltd.)

[0051] Experimental animals: Swiss mice were purchased from the Experimental Animal Department of Beijing University of Traditional Chinese Medicine.

[0052] Methods and results: 50 mice, weighing 20±2g, half male and half male, were randomly divided into 5 groups. The injection preparation of the present invention and the safflower injection were given to the tail vein of mice at 5 g / kg, once a day for 30 consecutive days, and the control group was given the same amount of normal saline. One hour after the last dose of the drug, the mice were driven into a special holder, and then th...

Embodiment 2

[0064] The effects of each group of preparations of the present invention and commercially available safflower injection on the formation of thrombus in rats were determined by thrombus method.

[0065] Experimental drug: normal saline (blank group) was provided by the laboratory of Beijing Qianluchun Technology Co., Ltd.

[0066] Commercially available safflower injection (Sichuan Ya'an Sanjiu Pharmaceutical Co., Ltd.)

[0067] Each group of preparations of the present invention (provided by the laboratory of Beijing Ganluchun Science and Technology Co., Ltd.)

[0068] Experimental animals: 50 rats with a body weight of 300-400 grams, male or female. Divide into 5 groups, 10 in each group.

[0069] Experimental method: Rats were anesthetized (sodium pentobarbital 30-40mg / kg, ip), fixed in the supine position, the trachea was separated, a plastic cannula was inserted, and the right common carotid artery and the left external jugular vein were separated. A 6 cm long silk thr...

Embodiment 3

[0081] The in vivo myocardial infarction method was used to determine the effects of each group of preparations of the present invention and commercially available safflower injection on myocardial infarction in rats.

[0082] Experimental drug: commercially available safflower injection (Sichuan Ya'an Sanjiu Pharmaceutical Co., Ltd.) each group of preparations of the present invention (provided by the laboratory of Beijing Ganluchun Science and Technology Co., Ltd.)

[0083] Experimental animals: 60 male rats weighing 250-300 grams, divided into 6 groups.

[0084] Experimental method: Take 60 male rats, lightly anesthetize the abdominal cavity with urethane 0.65g / kg, fix the dorsal position, use more than half of a rubber ball to connect to the artificial respirator, and carry out artificial respiration. Incise the skin at the midclavian line about 2 cm, bluntly dissect the base layer of the fourth or fifth intercostal space, open the chest cavity, cut the pericardium, gently...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a drug combination containing total ginsenoside and safflower yellow and its preparation and application, and its characteristic: it is composed of the extracted and purified total ginsenoside and safflower yellow and made into various preparations having the effect of curing cardiovascular and cerebrovascular diseases and acceptable in pharmacy, such as solid preparation and injection. The pharmacological test result shows that it better overcomes the danger of hemorrhage caused by long-term safflower application and has remarkable effect on the bad reactions caused by safflower application, safer to apply and having better pharmacological effect and higher safety as compared with the similar drugs in the markets.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicine pharmacy, and in particular relates to a pharmaceutical composition containing total ginsenosides and safflower yellow and its preparation and application Background technique [0002] Carthamustinctorins L. is a 1-year-old herb of Compositae. Its dried tubular flowers are commonly used in traditional Chinese medicine. It has the effects of promoting blood circulation, removing blood stasis, and relieving pain. Analgesic and anti-inflammatory agent; safflower injection is an injection made from safflower, which has the effect of promoting blood circulation and removing blood stasis. It is clinically used to treat obliterative cerebrovascular disease, coronary heart disease, and vasculitis. According to relevant literature reports, cardiovascular and cerebrovascular diseases kill 12 million people every year, close to 1 / 4 of the total number of deaths in the world, and become t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/08A61K9/14A61K9/20A61K9/48A61K31/704A61P9/00A61P9/10
Inventor 张正生
Owner 张正生
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap